Edgewise Therapeutics, Inc. EWTX
Set alert
At close · Oct 30
After hours · Oct 30, 5:15 PM ET
- YTD
- +56.73%
- 1 year
- +108.36%
- Open
- 38.72
- Prev close
- 38.91
- Mkt cap
- 4.22B
- Vol
- 967.48K
- Avg vol
- 1.45M
- EPS
- -1.86
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 38.02
- High
- 39.44
- Forward P/E
- -21.93
- Beta
- 0.35
- Short ratio
- 6.61
- Inst. own
- 112.25%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 5, 2026
- 50-d avg
- 41.43
- 200-d avg
- 36.22
- 1y target
- 52.62
News
-
2 weeks ago benzinga.com
William Blair Initiates Coverage On Edgewise Therapeutics with Outperform Rating
William Blair analyst Alethia Young initiates coverage on Edgewise Therapeutics (NASDAQ:EWTX) with a Outperform rating.
-
3 weeks ago benzinga.com
Edgewise Therapeutics Doses First Participant In EQUINOX-HFpEF Study Of EDG-15400 To Treat Adults With Symptomatic Heart Failure With Preserved Ejection Fraction
Edgewise Therapeutics, Inc. (Nasdaq: EWTX), a leading clinical-stage biopharmaceutical company focused on cardiometabolic diseases, today announced the dosing of the first patient in EQUINOX-HFpEF, a…
3 weeks ago prnewswire.com
Edgewise Therapeutics Doses First Patient in Phase 2 EQUINOX-HFpEF Trial of EDG-15400
– Phase 2 trial evaluating EDG-15400 in adults with symptomatic HFpEF with a LVEF of at least 50% – – EQUINOX-HFpEF trial design and EDG-15400 Phase 1 first-in-human data to be presented at HFSA 2026…
1 month ago prnewswire.com
Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules
BOULDER, Colo., Oct. 1, 2026 /PRNewswire/ -- Edgewise Therapeutics, Inc. ("Edgewise" or the "Company"), (Nasdaq: EWTX), a leading clinical-stage biopharmaceutical company focused on cardiovascular…
1 month ago seekingalpha.com
Edgewise Therapeutics, Inc. (EWTX) Discusses Differentiated Mechanism of Action of Cardiac Sarcomere Modulator EDG-7500 Transcript
Edgewise Therapeutics, Inc. (EWTX) Discusses Differentiated Mechanism of Action of Cardiac Sarcomere Modulator EDG-7500 Transcript
1 month ago prnewswire.com
Edgewise Therapeutics Unveils the Differentiated Mechanism of Action (MoA) of its Cardiac Sarcomere Modulator EDG-7500
- The MoA that targets the Regulatory Light Chain (RLC) has shown in preclinical models to improve cardiac relaxation while preserving systolic function and cardiac reserve - - Company to host…
-
1 month ago benzinga.com
HC Wainwright & Co. Maintains Buy on Edgewise Therapeutics, Raises Price Target to $57
HC Wainwright & Co. analyst Lander Egaña Gorroño maintains Edgewise Therapeutics (NASDAQ:EWTX) with a Buy and raises the price target from $45 to $57.
1 month ago schaeffersresearch.com
Biotech Options Buzz: UTHR, NMRA, EWTX
Biotech stocks are dominating today's unusual options volume list, with United Therapeutics Corporation (NASDAQ: UTHR), Neumora Therapeutics Inc (NASDAQ: NMRA), and Edgewise Therapeutics Inc (NASDAQ:…
1 month ago defenseworld.net
91,638 Shares in Edgewise Therapeutics, Inc. $EWTX Acquired by Hsbc Holdings PLC
Hsbc Holdings PLC purchased a new position in shares of Edgewise Therapeutics, Inc. (NASDAQ: EWTX) in the second quarter, according to the company in its most recent filing with the Securities and…
2 months ago prnewswire.com
Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules
BOULDER, Colo., Sept. 2, 2026 /PRNewswire/ -- Edgewise Therapeutics, Inc. ("Edgewise" or the "Company"), (Nasdaq: EWTX), a leading clinical-stage biopharmaceutical company focused on cardiovascular…
2 months ago prnewswire.com
Edgewise Therapeutics Announces Upcoming Late-Breaking Science Presentation at the European Society of Cardiology (ESC) Congress 2026
– Presentation highlights positive top-line data from 12-week Phase 2 CIRRUS-HCM trial with EDG-7500 in obstructive and nonobstructive hypertrophic cardiomyopathy (HCM) – BOULDER, Colo., Aug. 24,…
2 months ago seekingalpha.com
Edgewise Therapeutics: The Servier Deal Creates A Self-Funded Cardiovascular Platform
Edgewise Therapeutics (EWTX) has transformed into a well-capitalized cardiovascular drug developer following the $1.55B sale of sevasemten to Servier. EDG-7500, EWTX's lead asset, demonstrated robust…
-
2 months ago benzinga.com
Goldman Sachs Maintains Neutral on Edgewise Therapeutics, Raises Price Target to $36
Goldman Sachs analyst Paul Choi maintains Edgewise Therapeutics (NASDAQ:EWTX) with a Neutral and raises the price target from $32 to $36.
-
2 months ago benzinga.com
Edgewise Therapeutics Q2 EPS $(0.53) Misses $(0.47) Estimate
Edgewise Therapeutics (NASDAQ:EWTX) reported quarterly losses of $(0.53) per share which missed the analyst consensus estimate of $(0.47) by 12.77 percent. This is a 55.88 percent decrease over…
2 months ago prnewswire.com
Edgewise Therapeutics Reports Second Quarter 2026 Financial Results
– Announced positive top-line data from 12-week Phase 2 CIRRUS-HCM trial with EDG-7500 in obstructive and nonobstructive hypertrophic cardiomyopathy (HCM) – – Completed sale of sevasemten and…
-
3 months ago benzinga.com
Evercore ISI Group Maintains Outperform on Edgewise Therapeutics, Raises Price Target to $55
Evercore ISI Group analyst Cory Kasimov maintains Edgewise Therapeutics (NASDAQ:EWTX) with a Outperform and raises the price target from $45 to $55.
3 months ago prnewswire.com
Edgewise Therapeutics Completes Sale of Sevasemten for Up to $2.65 Billion, Strengthening Balance Sheet and Centering Company Focus on Cardiovascular Pipeline
— Edgewise receives $1.55 billion in upfront cash and is eligible to receive up to $1.1 billion in regulatory and commercial milestones — — Transaction creates strategically focused cardiovascular…
-
3 months ago benzinga.com
Oppenheimer Initiates Coverage On Edgewise Therapeutics with Outperform Rating, Announces Price Target of $51
Oppenheimer analyst Mazahir Alimohamed initiates coverage on Edgewise Therapeutics (NASDAQ:EWTX) with a Outperform rating and announces Price Target of $51.
-
3 months ago benzinga.com
Guggenheim Maintains Buy on Edgewise Therapeutics, Raises Price Target to $51
Guggenheim analyst Debjit Chattopadhyay maintains Edgewise Therapeutics (NASDAQ:EWTX) with a Buy and raises the price target from $41 to $51.
4 months ago prnewswire.com
Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules
BOULDER, Colo., July 1, 2026 /PRNewswire/ -- Edgewise Therapeutics, Inc. ("Edgewise" or the "Company"), (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company developing novel…
4 months ago benzinga.com
Micron To Rally Around 44%? Here Are 10 Top Analyst Forecasts For Thursday
Top analysts changed outlook on top names: Intuit downgraded, Alkermes price target raised, Carmax target increased, Sezzle target up, Biogen target raised, Progressive target cut.
-
4 months ago benzinga.com
RBC Capital Maintains Outperform on Edgewise Therapeutics, Raises Price Target to $59
RBC Capital analyst Leonid Timashev maintains Edgewise Therapeutics (NASDAQ:EWTX) with a Outperform and raises the price target from $48 to $59.
-
4 months ago benzinga.com
Delta Air Lines To Rally Around 12%? Here Are 10 Top Analyst Forecasts For Wednesday
Top Wall Street analysts changed outlook on top names. Baird raised prices for Ryder System and J B Hunt, Needham for Glaukos, B of A for CSX, Morgan Stanley for Charles River, and Bernstein for…
-
4 months ago benzinga.com
Goldman Sachs Maintains Neutral on Edgewise Therapeutics, Raises Price Target to $32
Goldman Sachs analyst Paul Choi maintains Edgewise Therapeutics (NASDAQ:EWTX) with a Neutral and raises the price target from $20 to $32.
4 months ago seekingalpha.com
Edgewise Therapeutics, Inc. (EWTX) Discusses Top Line Data From EDG-7500 Phase II CIRRUS-HCM Trial in Hypertrophic Cardiomyopathy Transcript
Edgewise Therapeutics, Inc. (EWTX) Discusses Top Line Data From EDG-7500 Phase II CIRRUS-HCM Trial in Hypertrophic Cardiomyopathy Transcript
4 months ago benzinga.com
Edgewise Therapeutics Reports Improvements In Heart Drug Trial
Edgewise Therapeutics Inc. (NASDAQ:EWTX) on Tuesday released topline results from the 12-week Part D cohort of its Phase 2 CIRRUS-HCM trial.
4 months ago benzinga.com
Edgewise Therapeutics Reports Improvements In Heart Drug Trial
Edgewise reports Phase 2 EDG-7500 data in thick heart muscles, showing symptom, biomarker, and heart function improvements.
-
4 months ago benzinga.com
HC Wainwright & Co. Reiterates Buy on Edgewise Therapeutics, Maintains $45 Price Target
HC Wainwright & Co. analyst Lander Egaña Gorroño reiterates Edgewise Therapeutics (NASDAQ:EWTX) with a Buy and maintains $45 price target.
4 months ago reuters.com
Edgewise shares slip after heart-disease drug trial data disappoints investors
Edgewise Therapeutics shares fell nearly 10% on Tuesday after the efficacy of its experimental heart-disease drug in a mid-stage study fell short of investor expectations.
4 months ago benzinga.com
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
-
4 months ago benzinga.com
Edgewise Therapeutics Says Topline Data From 12-week Phase 2 Part D CIRRUS-HCM trial of EDG-7500 In Obstructive And Nonobstructive Hypertrophic Cardiomyopathy Show No Relationship Observed Between Multiple Measures Of Systolic Function And Concentration Of EDG-7500
– No relationship observed between EDG-7500 exposure and LVEF; no LVEF reductions below 50% –– Consistent and clinically meaningful improvements observed in echocardiogram parameters, biomarkers,…
4 months ago prnewswire.com
Edgewise Therapeutics Announces Positive Top-Line Data from 12-Week Phase 2 CIRRUS-HCM Trial with EDG-7500 in Obstructive and Nonobstructive Hypertrophic Cardiomyopathy (HCM)
– No relationship observed between EDG-7500 exposure and LVEF; no LVEF reductions below 50% – – Consistent and clinically meaningful improvements observed in echocardiogram parameters, biomarkers,…
5 months ago seekingalpha.com
Edgewise: 'Buy' On Muscular Dystrophy Program Sale And EDG-7500 Advancement
Edgewise Therapeutics remains a "Buy," driven by pipeline focus and a transformative $2.65B sale of its muscular dystrophy program to Servier. Company will use the $1.55B upfront cash to fully fund…
5 months ago prnewswire.com
Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules
BOULDER, Colo., June 3, 2026 /PRNewswire/ -- Edgewise Therapeutics, Inc. ("Edgewise" or the "Company"), (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company developing novel…
5 months ago zacks.com
Edgewise Therapeutics Stock Hits Record High on $2.65B Servier Deal
EWTX surges 18% to a record high after striking a $2.65 billion neuromuscular business divestiture deal with Servier, sharpening focus on its cardiovascular pipeline.
-
5 months ago benzinga.com
HC Wainwright & Co. Maintains Buy on Edgewise Therapeutics, Raises Price Target to $45
HC Wainwright & Co. analyst Lander Egaña Gorroño maintains Edgewise Therapeutics (NASDAQ:EWTX) with a Buy and raises the price target from $42 to $45.
-
5 months ago benzinga.com
RBC Capital Maintains Outperform on Edgewise Therapeutics, Lowers Price Target to $48
RBC Capital analyst Leonid Timashev maintains Edgewise Therapeutics (NASDAQ:EWTX) with a Outperform and lowers the price target from $50 to $48.
-
5 months ago benzinga.com
Wedbush Maintains Outperform on Edgewise Therapeutics, Raises Price Target to $52
Wedbush analyst Laura Chico maintains Edgewise Therapeutics (NASDAQ:EWTX) with a Outperform and raises the price target from $46 to $52.
5 months ago benzinga.com
Optimum Communications, Fluence Energy, Virgin Galactic And Other Big Stocks Moving Higher Today
Several stocks, including Optimum Communications Services, surged while Dow fell. Technology, energy, and aerospace stocks saw notable gains.
5 months ago reuters.com
Edgewise to sell muscle dystrophy business to Servier for up to $2.65 billion
Biotech firm Edgewise Therapeutics said on Monday it would sell its experimental muscular dystrophy drug and related business to France's Servier for up to $2.65 billion.
-
5 months ago benzinga.com
Edgewise To Sell Its Muscular Dystrophy Business To Servier For $1.55B In Cash Up Front And Up To $1.1B In Further Milestone Payments For Aggregate Potential Sum Of Up To $2.65B
The transaction meaningfully strengthens Edgewise's balance sheet, providing enhanced financial flexibility and sharpening the Company's strategic focus to accelerate and unlock the full potential of…
-
5 months ago benzinga.com
Edgewise Therapeutics Q1 EPS $(0.46) Beats $(0.50) Estimate
Edgewise Therapeutics (NASDAQ:EWTX) reported quarterly losses of $(0.46) per share which beat the analyst consensus estimate of $(0.50) by 8 percent. This is a 6.98 percent decrease over losses of…
6 months ago benzinga.com
Rockwell Automation Posts Upbeat Q2 Results, Joins EverQuote, DigitalOcean And Other Big Stocks Moving Higher On Tuesday
Dow Jones up 200 points, Rockwell Automation shares rise 10.8% on strong earnings and raised guidance. Other big gainers include EverQuote, Sterling Infrastructure, and DigitalOcean.
6 months ago benzinga.com
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
-
10 months ago benzinga.com
Gold Edges Lower; Omeros Shares Jump
Gold Edges Lower; Omeros Shares Jump
10 months ago benzinga.com
Dynavax Technologies, Omeros, Agios Pharmaceuticals, Nike And Other Big Stocks Moving Higher On Wednesday
Dynavax Technologies, Omeros, Agios Pharmaceuticals, Nike And Other Big Stocks Moving Higher On Wednesday
10 months ago benzinga.com
10 Health Care Stocks Whale Activity In Today's Session
10 Health Care Stocks Whale Activity In Today's Session
10 months ago benzinga.com
Carnival Posts Strong Q4 Earnings, Joins Amicus Therapeutics, Biomarin Pharmaceutical And Other Big Stocks Moving Higher On Friday
Carnival Posts Strong Q4 Earnings, Joins Amicus Therapeutics, Biomarin Pharmaceutical And Other Big Stocks Moving Higher On Friday
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Monday's Pre-Market Session
12 Health Care Stocks Moving In Monday's Pre-Market Session
1 year ago benzinga.com
Tesla, Nvidia, Apple And Other Big Stocks Moving Lower In Monday's Pre-Market Session
Tesla, Nvidia, Apple And Other Big Stocks Moving Lower In Monday's Pre-Market Session